NBIX
Neurocrine Biosciences Inc
138.90$
-0.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 2.2% | 1.6% | 1.5% | 1.6% | 1.3% | 1.5% | 1.6% | 1.6% | 1.8% | 2.2% | 1.7% | 2.4% | 2.0% | |
| 97.8% | 98.4% | 98.5% | 98.4% | 98.7% | 98.5% | 98.4% | 98.4% | 98.2% | 97.8% | 98.3% | 97.6% | 98.0% | |
| 28.5% | 26.7% | 30.9% | 32.4% | 31.3% | 29.6% | 46.0% | 35.5% | 31.5% | 32.1% | 36.4% | 34.1% | 33.5% | |
| 40.9% | 42.5% | 47.2% | 41.0% | 37.7% | 45.8% | 48.3% | 41.6% | 36.7% | 37.5% | 39.1% | 45.8% | 40.1% | |
| 69.4% | 69.2% | 79.3% | 73.8% | 69.2% | 75.9% | 94.3% | 77.2% | 68.2% | 71.6% | 75.5% | 81.6% | 74.6% | |
| 28.3% | 29.2% | 19.3% | 24.6% | 29.5% | 22.6% | 4.1% | 21.2% | 30.1% | 26.2% | 22.8% | 16.0% | 23.4% | |
| 0.2% | 0.2% | 0.2% | 8.4% | – | – | – | 0.0% | – | – | – | 0.3% | – | |
| 23.2% | 38.5% | 6.7% | 16.7% | 30.6% | 25.9% | 2.6% | 23.2% | 36.7% | 29.7% | 30.3% | 16.9% | 27.9% | |
| 6.5% | 9.8% | -1.7% | 5.7% | 9.7% | 9.5% | 1.2% | 7.6% | 10.4% | 10.6% | 6.0% | 1.9% | 7.0% | |
| 16.7% | 28.7% | 8.4% | 11.0% | 20.9% | 16.4% | 1.4% | 15.6% | 26.4% | 19.1% | 24.3% | 15.1% | 20.9% | |
| 24.5% | 39.8% | 21.6% | 26.3% | 30.8% | 28.9% | 5.5% | 24.3% | 37.7% | 29.2% | 23.7% | 19.8% | 27.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.